Videos

Morning chaos and evening crashes call for different solutions within the same treatment plan. The panel closes by tailoring extended-release strategies to cover patients around the clock.

Patients weigh trade-offs differently than clinicians do, and they arrive having already consulted the internet. The panel examines what to honor in shared decision-making without sacrificing the evidence.

The field finally has new targets after decades anchored to monoamines. Dr. DeBattista explains why he welcomes them while predicting, from experience, that most of them will not work out.

Expert shares how AI may support drug development and clinical practice.

Experts discuss psychopharmacology from discovery of CYP enzymes to modern serum testing.

How can AI be useful for modeling in diagnosis and clinical trials?

Explore why meds fall short for complex trauma—and how EMDR, body-based therapies, and psychedelic-assisted treatment reshape healing, safety, and time perspective.

Generic antidepressant switching has little supporting evidence, and Erin Crown explains why she often chooses early augmentation instead, guided by each patient's risk factors.

Deciding whether to switch medications or build on a partial response shapes every subsequent treatment choice. Dr. Citrome outlines the criteria that separate a true nonresponse from a foundation worth augmenting.

New AI methods investigate clearer depression and schizophrenia subgroups from small, noisy trials, using model abstention to boost interpretability and improve patient stratification.

Titration is not a formality; it is where treatment succeeds or quietly fails. The panel discusses how to titrate assertively while rebuilding trust with previously discouraged patients.

Not all ADHD medications behave the same way in the same patient. The panel details how to match formulation to individual context and read the earliest signs of a suboptimal fit.

Stopping an antidepressant is as much a clinical act as starting one, and it is often done badly. Dr. Clayton reviews when to discontinue and when a slower taper is warranted.

A patient who is better but not well presents the field's most common decision. The panel works through the thresholds that separate optimizing, switching, combining, and augmenting.

Perimenopause triggers mood and cognitive shifts that can mimic or worsen serious mental illness; learn symptom clues, estrogen’s role, and why coordinated care matters.

In-person visits let Erin Crown read incongruence between what a patient says and how they present, and one encounter years ago showed her exactly why that matters.

A vague sense of 'blah' is often the last symptom to lift. Dr. Harding and Dr. Citrome examine why anhedonia and disrupted sleep persist longest, and how tracking them closely reveals early warning signs.

Gus Alva, MD, DFAPA, joins Erin Crown to discuss how regional meetings, industry exchange, and emerging treatments can help clinicians avoid burnout and better serve patients.

Medication access and cost shape ADHD outcomes as much as the prescription itself. The panel examines shortages, pricing, and the real economic toll of inadequately treated ADHD.

Patches, liquids, and a newly approved triple reuptake inhibitor are expanding the ADHD treatment toolkit. The panel discusses when to reach beyond familiar medications and how to build patient trust in doing so.

Two decades after a landmark STAR*D trial recalibrated expectations, Dr. DeBattista argues the standard of care has barely moved, and that measurement-based care remains the underused lever.

The side effect that stops the drug is usually the one nobody warned about. The panel works through what belongs in the first conversation and how often to reassess for suicidality.

A patient's improving score does not always translate into a patient who feels better, and Erin Crown explains how anhedonia and cognitive symptoms account for the gap.

More than half of patients treated for depression don't believe full remission is achievable. The panel explores what success should mean to the patient in front of you, and why patients rarely admit they've stopped taking a medication.

Closing the discussion, the panel offers practical guidance on patient education, ongoing clinical learning, and community-based research opportunities to help clinicians move schizophrenia care forward.

Behind every extended-release stimulant is an engineering problem: how to release medication predictably over hours. The panel breaks down the microparticle and polymer technologies making that possible.

Caregivers carry an enormous, often invisible burden in schizophrenia care. The panel discusses how curiosity, communication, and community resources can support families while helping patients hold onto hope.

Sensory sensitivity, weekend flexibility, and hyperfocus all shape how adults actually take their ADHD medication. The panel explains why formulation choice can matter as much as the molecule.

A TSH alone usually suffices, serial testing can feed anxiety, and age-specific ranges matter, an endocrinologist tells psychiatrists.

Patients often wait years to seek therapy, arriving in crisis as gaps between prescribers and therapists slow coordinated care and complicate relationship healing.